Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
74.89(c) 74.91(c) 74.44(c) 73.89(c) 73.34(c) Last
34 192 411 30 179 887 21 442 236 15 345 277 13 898 964 Volume
-5.39% +0.03% -0.63% -0.74% -0.74% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 48 572 M - -
Net income 2021 12 378 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 15,1x
Yield 2021 3,54%
Sales 2022 56 117 M - -
Net income 2022 16 465 M - -
Net Debt 2022 13 993 M - -
P/E ratio 2022 11,4x
Yield 2022 3,91%
Capitalization 185 B 185 B -
EV / Sales 2021 4,24x
EV / Sales 2022 3,55x
Nbr of Employees 73 500
Free-Float 70,5%
More Financials
Company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and... 
Sector
Pharmaceuticals
Calendar
12/14Ex-dividend day for
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MERCK & CO., INC.
12/03FDA Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Treatment for Adult and Pedi..
BU
12/03Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19
DJ
12/03Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupira..
AQ
12/03Canada Signs Deal for 1 Mln Doses of Pfizer Covid Antiviral and 500K Merck's Covid Pill
MT
12/03Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
12/03Bristol-Myers Squibb's Supplemental Biologics License Application for Drug Co-Developed..
MT
12/03KYODO NEWS DIGEST : Dec. 3, 2021 -3-
AQ
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/03Nikkei 225 Gains 1% on Merck Covid-19 Drug Application
MT
12/03U.S. pharma Merck unit seeks Japan's approval of oral COVID drug
AQ
12/03Merck & Co. Said to Seek Japanese Regulatory Nod for COVID-19 Pill
MT
12/03Merck Applies for Covid Pill Approval in Japan, Nikkei Reports
DJ
12/03Tokyo stocks end higher on hopes for COVID-19 oral treatment drug
AQ
12/02U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for..
AQ
12/02Federal Court Of Appeal Dismisses Appeal, Upholds Strict Interpretation Of Patent Listi..
AQ
More news
News in other languages on MERCK & CO., INC.
12/03Merck & Co schließt Liefervereinbarung mit Kanada für Covid-19-Medikament
12/03MERCK : examen prioritaire de la FDA pour le reblozyl
12/03Le Nikkei 225 gagne 1 % grâce à la demande d'homologation du médicament Covid-19 de Mer..
12/03Merck & Co. Merck chercherait à obtenir l'aval des autorités japonaises pour la pilule ..
12/02CORONA-BLOG/Spahn sichert Deutschland Covid-Medikament Lagevrio von Merck
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,34 $
Average target price 95,25 $
Spread / Average Target 29,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.34%185 253
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641